Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies

NCT06003387 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT06003387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06003387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies
Lead sponsor
CSL Behring
Phase
Phase 3
Overall status
Recruiting
Start date
January 30, 2024
Completion date
April 2, 2032
Enrollment
35 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b